ALVO OAKTREE ACQUISITION CORP II

Alvotech Annual General Meeting to be held June 25, 2025

Alvotech Annual General Meeting to be held June 25, 2025

The Annual General Meeting of Alvotech will be held on Wednesday June 25, 2025, at 09.00 a.m. CEST at the premises of Arendt & Medernach at 41A, Avenue John F. Kennedy L-1855 Luxembourg, Grand Duchy of Luxembourg.

Reference is made to the attached document with regard to the final agenda.

Meeting materials and all further information about the Annual General Meeting is available on the Alvotech website:

CONTACTS



Alvotech Investor Relations

Benedikt Stefansson, VP

Attachment



EN
26/05/2025

Underlying

ALVOOAKTREE ACQUISITION CORP II

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OAKTREE ACQUISITION CORP II

 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Alvotech and Advanz Pharma Extend Strategic Partnership to Commerciali...

Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programsThe agreement includes proposed biosimilars to Ilaris® (canakinumab), Kesimpta® (ofatumumab) and an additional early-stage undisclosed biosimilar candidate REYKJAVIK, ICELAND and LONDON, UK (May 28, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for...

12h / 14m 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Advanz Pharma semur við Alvotech um rétt til markaðssetningar þriggja ...

Advanz Pharma semur við Alvotech um rétt til markaðssetningar þriggja fyrirhugaðra hliðstæða til viðbótar í Evrópu Samningurinn felur í sér greiðslu við undirritun og áfangagreiðslur, samtals að upphæð allt að 23,1 milljarður króna (160 milljónir evra), en að auki munu samstarfsaðilarnir skipta með sér tekjum af sölu lyfjannaAdvanz Pharma öðlast einkarétt til markaðssetningar í Evrópu á þremur fyrirhuguðum líftæknilyfjahliðstæðum frá Alvotech, til viðbótar við fyrra samkomulagSamið er um fyrirhugaðar hliðstæður við líftæknilyfin Ilaris (canakinumab), Kesimpta (ofatumumab) og ónefnt frumlyf ...

12h / 14m 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Alvotech and Advanz Pharma Extend Strategic Partnership to Commerciali...

Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programsThe agreement includes proposed biosimilars to Ilaris® (canakinumab), Kesimpta® (ofatumumab) and an additional early-stage undisclosed biosimilar candidate REYKJAVIK, Iceland and LONDON, May 28, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimila...

12h / 14m 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Alvotech Annual General Meeting to be held June 25, 2025

Alvotech Annual General Meeting to be held June 25, 2025 The Annual General Meeting of Alvotech will be held on Wednesday June 25, 2025, at 09.00 a.m. CEST at the premises of Arendt & Medernach at 41A, Avenue John F. Kennedy L-1855 Luxembourg, Grand Duchy of Luxembourg. Reference is made to the attached document with regard to the final agenda. Meeting materials and all further information about the Annual General Meeting is available on the Alvotech website: CONTACTS Alvotech Investor RelationsBenedikt Stefansson, VP Attachment

May 26, 2025 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Aðalfundur Alvotech boðaður 25. júní 2025

Aðalfundur Alvotech boðaður 25. júní 2025 Aðalfundur Alvotech verður haldinn miðvikudaginn 25. júní 2025, kl. 09.00 CEST á skrifstofu Arendt & Medernach að 41A Avenue John F. Kennedy, L-1855 Lúxemborg. Dagskrá fundarins er að finna í meðfylgjandi viðhengi. Fundurinn fer fram á ensku. Fundargögn og allar frekari upplýsingar varðandi aðalfundinn er hægt að nálgast á heimasíðu félagsins  Nánari upplýsingar veitir: Alvotech, fjárfestatengslBenedikt Stefánsson, forstöðumaður Viðhengi

May 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch